Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs placebo in EB simplex generalized severe (12-week)
2020-001542-19Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epidermolysis bullosa simplex (EBS) and epidermolysis bullosa (EB) comparing Ixekizumab Q2W with Placebo (2 arms). Primary endpoint: Dermatologic quality of life responder rate at week 12. Started Apr 2020; status: active.
02
Drugs
ixekizumab
03
Conditions
epidermolysis bullosa simplex (EBS)epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2020-001542-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001542-19.